ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35049
0,00%
Bitcoin
66.565,98
0,56%
Brent Oil
82,275
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. TScan Therapeutics Inc (TCRX)

  7. TScan Therapeutics Inc (TCRX) Notícias

TCRX

TScan Therapeutics (TCRX)

TScan Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TCRX
DataHoraFonteTítuloCódigoCompanhia
14/06/202417:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TCRXTScan Therapeutics Inc
14/06/202417:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TCRXTScan Therapeutics Inc
14/06/202408:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TCRXTScan Therapeutics Inc
14/06/202408:00GlobeNewswire Inc.TScan Therapeutics Announces Updates to its Board of DirectorsNASDAQ:TCRXTScan Therapeutics Inc
30/05/202408:00GlobeNewswire Inc.TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare ConferenceNASDAQ:TCRXTScan Therapeutics Inc
29/05/202408:00GlobeNewswire Inc.TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme MalignanciesNASDAQ:TCRXTScan Therapeutics Inc
13/05/202408:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TCRXTScan Therapeutics Inc
13/05/202408:00GlobeNewswire Inc.TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:TCRXTScan Therapeutics Inc
09/05/202408:00GlobeNewswire Inc.TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid TumorsNASDAQ:TCRXTScan Therapeutics Inc
24/04/202417:05GlobeNewswire Inc.TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:TCRXTScan Therapeutics Inc
24/04/202412:03GlobeNewswire Inc.TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:TCRXTScan Therapeutics Inc
22/04/202418:01GlobeNewswire Inc.TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:TCRXTScan Therapeutics Inc
19/04/202411:05GlobeNewswire Inc.TScan Therapeutics Announces Closing of Upsized Public OfferingNASDAQ:TCRXTScan Therapeutics Inc
17/04/202401:30GlobeNewswire Inc.TScan Therapeutics Announces Pricing of Upsized $150 Million Public OfferingNASDAQ:TCRXTScan Therapeutics Inc
16/04/202417:25GlobeNewswire Inc.TScan Therapeutics Announces Launch of $125 Million Proposed Public OfferingNASDAQ:TCRXTScan Therapeutics Inc
16/04/202417:01GlobeNewswire Inc.TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term PrioritiesNASDAQ:TCRXTScan Therapeutics Inc
08/04/202409:00GlobeNewswire Inc.TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical OfficerNASDAQ:TCRXTScan Therapeutics Inc
02/04/202408:00GlobeNewswire Inc.TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:TCRXTScan Therapeutics Inc
06/03/202418:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TCRXTScan Therapeutics Inc
06/03/202409:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TCRXTScan Therapeutics Inc
14/02/202418:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TCRXTScan Therapeutics Inc
29/08/202309:02Dow Jones NewsTScan Gets FDA Clearance of Investigational New Drug Application for Cancer TreatmentNASDAQ:TCRXTScan Therapeutics Inc
24/07/202320:31Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TCRXTScan Therapeutics Inc
29/06/202309:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRXTScan Therapeutics Inc
15/06/202319:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRXTScan Therapeutics Inc
12/06/202317:31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:TCRXTScan Therapeutics Inc
08/06/202314:26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TCRXTScan Therapeutics Inc
06/06/202311:25Dow Jones NewsTScan Therapeutics Shares Rise 17% After FDA Clears IND for Cancer TreatmentNASDAQ:TCRXTScan Therapeutics Inc
02/06/202317:07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TCRXTScan Therapeutics Inc
02/06/202317:07Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:TCRXTScan Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TCRX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
RRRP3
3R Petroleum Oleo E Gas ... ON
BOV
IDIV
Dividend
BOV
TOTS3
TOTVS ON
BOV
BRBI11
BR PARTNERS UNT N2
BOV
HAGA3
HAGA ON
BOV
BPAC11
BTG PACTUAL UNT
BOV
HBOR3
HELBOR ON
BOV
PRIO3
PETRORIO ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
CMIN3
CSN Mineracao S.A ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados